CA2463725A1 - Compilations of nucleic acids and arrays and methods of using them - Google Patents
Compilations of nucleic acids and arrays and methods of using them Download PDFInfo
- Publication number
- CA2463725A1 CA2463725A1 CA002463725A CA2463725A CA2463725A1 CA 2463725 A1 CA2463725 A1 CA 2463725A1 CA 002463725 A CA002463725 A CA 002463725A CA 2463725 A CA2463725 A CA 2463725A CA 2463725 A1 CA2463725 A1 CA 2463725A1
- Authority
- CA
- Canada
- Prior art keywords
- syndrome
- locus
- chromosome
- nucleic acid
- segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 757
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 748
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 748
- 238000000034 method Methods 0.000 title claims abstract description 195
- 238000003491 array Methods 0.000 title abstract description 104
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 487
- 208000031404 Chromosome Aberrations Diseases 0.000 claims abstract description 87
- 230000005861 gene abnormality Effects 0.000 claims abstract description 66
- 230000002759 chromosomal effect Effects 0.000 claims abstract description 49
- 238000012217 deletion Methods 0.000 claims abstract description 43
- 230000037430 deletion Effects 0.000 claims abstract description 43
- 238000001514 detection method Methods 0.000 claims abstract description 38
- 238000003745 diagnosis Methods 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 31
- 208000036878 aneuploidy Diseases 0.000 claims abstract description 18
- 231100001075 aneuploidy Toxicity 0.000 claims abstract description 18
- 210000000349 chromosome Anatomy 0.000 claims description 487
- 238000009396 hybridization Methods 0.000 claims description 106
- 108020004414 DNA Proteins 0.000 claims description 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 68
- 201000010099 disease Diseases 0.000 claims description 61
- 201000001388 Smith-Magenis syndrome Diseases 0.000 claims description 46
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 41
- 101150084935 PTER gene Proteins 0.000 claims description 38
- 239000000758 substrate Substances 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 36
- 206010051956 Trichorhinophalangeal syndrome Diseases 0.000 claims description 31
- 238000002372 labelling Methods 0.000 claims description 31
- 230000003252 repetitive effect Effects 0.000 claims description 28
- 208000034431 Adrenal hypoplasia congenita Diseases 0.000 claims description 27
- 208000005875 Alternating hemiplegia of childhood Diseases 0.000 claims description 27
- 230000005856 abnormality Effects 0.000 claims description 27
- 208000003449 Classical Lissencephalies and Subcortical Band Heterotopias Diseases 0.000 claims description 26
- 201000004246 Miller-Dieker lissencephaly syndrome Diseases 0.000 claims description 26
- 208000035022 Miller-Dieker syndrome Diseases 0.000 claims description 26
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 26
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 210000004507 artificial chromosome Anatomy 0.000 claims description 23
- 238000005406 washing Methods 0.000 claims description 23
- 230000000052 comparative effect Effects 0.000 claims description 22
- 239000007850 fluorescent dye Substances 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 21
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 19
- 206010050638 Langer-Giedion syndrome Diseases 0.000 claims description 19
- 208000006254 Wolf-Hirschhorn Syndrome Diseases 0.000 claims description 19
- 210000001766 X chromosome Anatomy 0.000 claims description 19
- 239000000975 dye Substances 0.000 claims description 19
- 206010069382 Hereditary neuropathy with liability to pressure palsies Diseases 0.000 claims description 18
- 201000003702 glycerol kinase deficiency Diseases 0.000 claims description 18
- 208000026203 inborn glycerol kinase deficiency Diseases 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 201000006532 trichorhinophalangeal syndrome type II Diseases 0.000 claims description 18
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 17
- 208000035378 Trichorhinophalangeal syndrome type 2 Diseases 0.000 claims description 17
- 210000002593 Y chromosome Anatomy 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 16
- 208000001001 X-linked ichthyosis Diseases 0.000 claims description 16
- 208000026079 recessive X-linked ichthyosis Diseases 0.000 claims description 16
- 201000000866 velocardiofacial syndrome Diseases 0.000 claims description 16
- 201000011374 Alagille syndrome Diseases 0.000 claims description 15
- 210000001106 artificial yeast chromosome Anatomy 0.000 claims description 15
- -1 chloromethylphenyl moiety Chemical group 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 14
- 206010049644 Williams syndrome Diseases 0.000 claims description 13
- 150000001875 compounds Chemical group 0.000 claims description 13
- 206010011385 Cri-du-chat syndrome Diseases 0.000 claims description 12
- 208000001804 Monosomy 5p Diseases 0.000 claims description 12
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 claims description 12
- 208000020570 3p deletion syndrome Diseases 0.000 claims description 11
- 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 claims description 11
- 208000006720 Potocki-Shaffer syndrome Diseases 0.000 claims description 11
- 201000007960 WAGR syndrome Diseases 0.000 claims description 11
- 210000000688 human artificial chromosome Anatomy 0.000 claims description 11
- 230000008771 sex reversal Effects 0.000 claims description 11
- 206010048911 Lissencephaly Diseases 0.000 claims description 10
- 208000034079 Monosomy 9p Diseases 0.000 claims description 10
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 10
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 10
- 208000004780 Potocki-Lupski syndrome Diseases 0.000 claims description 10
- 206010039281 Rubinstein-Taybi syndrome Diseases 0.000 claims description 10
- 201000001329 chromosome 9p deletion syndrome Diseases 0.000 claims description 10
- 208000014817 lissencephaly spectrum disease Diseases 0.000 claims description 10
- 238000013519 translation Methods 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 9
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 9
- 210000001161 mammalian embryo Anatomy 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 9
- 206010010539 Congenital megacolon Diseases 0.000 claims description 8
- 208000004592 Hirschsprung disease Diseases 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 210000004252 chorionic villi Anatomy 0.000 claims description 8
- 238000000799 fluorescence microscopy Methods 0.000 claims description 8
- 239000013642 negative control Substances 0.000 claims description 8
- 239000013641 positive control Substances 0.000 claims description 8
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 7
- 206010008748 Chorea Diseases 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 7
- 208000013667 paroxysmal dyskinesia Diseases 0.000 claims description 7
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 7
- 206010071437 Dyschondrosteosis Diseases 0.000 claims description 6
- 201000001934 Leri-Weill dyschondrosteosis Diseases 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 208000009575 Angelman syndrome Diseases 0.000 claims description 5
- 241000702191 Escherichia virus P1 Species 0.000 claims description 5
- 208000026724 Waardenburg syndrome Diseases 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 210000004381 amniotic fluid Anatomy 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 238000004590 computer program Methods 0.000 claims description 4
- 239000013601 cosmid vector Substances 0.000 claims description 4
- 150000004292 cyclic ethers Chemical group 0.000 claims description 4
- 210000002308 embryonic cell Anatomy 0.000 claims description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 201000009009 Charcot-Marie-Tooth disease type 1A Diseases 0.000 claims 4
- 238000004890 malting Methods 0.000 claims 1
- 230000003321 amplification Effects 0.000 abstract description 24
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 24
- 238000004393 prognosis Methods 0.000 abstract description 16
- 206010008805 Chromosomal abnormalities Diseases 0.000 abstract description 10
- 239000000523 sample Substances 0.000 description 142
- 239000012634 fragment Substances 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 208000036626 Mental retardation Diseases 0.000 description 16
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 230000003595 spectral effect Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 239000013615 primer Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- 230000007547 defect Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 230000005945 translocation Effects 0.000 description 8
- 238000000018 DNA microarray Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 102000016911 Deoxyribonucleases Human genes 0.000 description 6
- 108010053770 Deoxyribonucleases Proteins 0.000 description 6
- 102100023903 Glycerol kinase Human genes 0.000 description 6
- 201000007493 Kallmann syndrome Diseases 0.000 description 6
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000001815 facial effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000009395 genetic defect Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 208000033929 Birt-Hogg-Dubé syndrome Diseases 0.000 description 5
- 206010056740 Genital discharge Diseases 0.000 description 5
- 206010028182 Multiple congenital abnormalities Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 208000037280 Trisomy Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002559 cytogenic effect Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 206010021198 ichthyosis Diseases 0.000 description 4
- 210000000723 mammalian artificial chromosome Anatomy 0.000 description 4
- 208000004141 microcephaly Diseases 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000010453 quartz Substances 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 201000006892 Charcot-Marie-Tooth disease type 1 Diseases 0.000 description 3
- 208000031639 Chromosome Deletion Diseases 0.000 description 3
- 206010012559 Developmental delay Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100037260 Gap junction beta-1 protein Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 206010068052 Mosaicism Diseases 0.000 description 3
- 208000007379 Muscle Hypotonia Diseases 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 208000036623 Severe mental retardation Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 239000005350 fused silica glass Substances 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
- 238000003499 nucleic acid array Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- 208000034076 BOR syndrome Diseases 0.000 description 2
- 208000017843 C syndrome Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000004468 Craniofacial Abnormalities Diseases 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- 206010066054 Dysmorphism Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000010086 Hypertelorism Diseases 0.000 description 2
- 206010020771 Hypertelorism of orbit Diseases 0.000 description 2
- 206010058359 Hypogonadism Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 201000008645 Joubert syndrome Diseases 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- 208000025634 Multiple congenital anomalies/dysmorphic syndrome-intellectual disability Diseases 0.000 description 2
- 101150063042 NR0B1 gene Proteins 0.000 description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010037213 Psychomotor retardation Diseases 0.000 description 2
- 108010066717 Q beta Replicase Proteins 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 2
- 102100038021 Steryl-sulfatase Human genes 0.000 description 2
- 102000005262 Sulfatase Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000035167 Xp21 deletion syndrome Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 208000008303 aniridia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000001444 catalytic combustion detection Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000701 chemical imaging Methods 0.000 description 2
- 108010015416 connexin 32 Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000022734 developmental defect during embryogenesis Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008775 paternal effect Effects 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 108060007951 sulfatase Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- CMILCJDHCOUGJQ-UHFFFAOYSA-N 1-methylideneisoindole Chemical compound C1=CC=C[C]2C([CH2])=NC=C21 CMILCJDHCOUGJQ-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 208000000363 Agenesis of Corpus Callosum Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000018311 Autosomal trisomy Diseases 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 208000000380 Cafe-au-Lait Spots Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010048824 Cerebral ventricle dilatation Diseases 0.000 description 1
- 201000008993 Charcot-Marie-Tooth disease type 1C Diseases 0.000 description 1
- 206010008754 Choreoathetosis Diseases 0.000 description 1
- 208000036086 Chromosome Duplication Diseases 0.000 description 1
- 241001630118 Chrysomphalus bifasciculatus Species 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 208000008020 Cohen syndrome Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010011498 Cryptorchism Diseases 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000035976 Developmental Disabilities Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000027877 Disorders of Sex Development Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000008517 Dysequilibrium syndrome Diseases 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001692 Esotropia Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 101150116966 Ext1 gene Proteins 0.000 description 1
- 208000023281 Fallot tetralogy Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 208000016311 Freckling Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000009396 Group II Malformations of Cortical Development Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000603323 Homo sapiens Nuclear receptor subfamily 0 group B member 1 Proteins 0.000 description 1
- 101100477520 Homo sapiens SHOX gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 206010064024 Intestinal malrotation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 208000030979 Language Development disease Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010068749 Lung cyst Diseases 0.000 description 1
- 208000033334 Maternal uniparental disomy Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027543 Micrognathia Diseases 0.000 description 1
- 208000002598 Micrognathism Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 208000033128 Multiple osteochondromas Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000027419 Muscular hypotonia Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000013355 Mycteroperca interstitialis Species 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 101150082519 PLP1 gene Proteins 0.000 description 1
- 101150038744 PMP22 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000010633 Partial duplication of the short arm of chromosome 3 Diseases 0.000 description 1
- 201000009928 Patau syndrome Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000008708 Prognathism Diseases 0.000 description 1
- 208000023109 Prominent forehead Diseases 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 208000033787 Rare developmental defect during embryogenesis Diseases 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010038486 Renal neoplasms Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101150059736 SRY gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004487 Satellite DNA Proteins 0.000 description 1
- 206010059594 Secondary hypogonadism Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 208000020568 Severe short stature Diseases 0.000 description 1
- 102000048489 Short Stature Homeobox Human genes 0.000 description 1
- 108700025071 Short Stature Homeobox Proteins 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 239000004965 Silica aerogel Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 201000003005 Tetralogy of Fallot Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010044686 Trisomy 13 Diseases 0.000 description 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 101150046474 Vhl gene Proteins 0.000 description 1
- 208000018181 Waardenburg-Shah syndrome Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- OYVGFASYJHUBSP-YGOYTEALSA-N [[(2r,3s,5r)-5-(4,5-diamino-2-oxopyrimidin-1-yl)-3-hydroxy-5-prop-2-ynyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(N)=CN1[C@]1(CC#C)O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 OYVGFASYJHUBSP-YGOYTEALSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 208000015150 agyria-pachygyria type 1 Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000025261 autosomal dominant disease Diseases 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-L benzyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-L 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 208000036107 bilateral Madelung deformity Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 201000006715 brachydactyly Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 208000001020 chondrodysplasia punctata Diseases 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000000160 cryptorchidism Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000020 developmental retardation Toxicity 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000027110 duplication/inversion 15q11 Diseases 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005216 enteric neuron Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000002566 gonadal dysgenesis Diseases 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 208000003064 gonadoblastoma Diseases 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000010903 hereditary multiple osteochondromas Diseases 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000055071 human NR0B1 Human genes 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 208000033066 hyperinsulinemic hypoglycemia Diseases 0.000 description 1
- 235000019559 hyposmia Nutrition 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000006237 infantile hypercalcemia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000029443 keratinization disease Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000035853 malformation syndrome Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000030454 monosomy Diseases 0.000 description 1
- XTGGILXPEMRCFM-UHFFFAOYSA-N morpholin-4-yl carbamate Chemical compound NC(=O)ON1CCOCC1 XTGGILXPEMRCFM-UHFFFAOYSA-N 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008859 olfactory neuroblastoma Diseases 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 208000007138 otopalatodigital syndrome type 1 Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 201000003044 parietal foramina Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 238000012802 pre-warming Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 208000028103 tetrasomy 9p Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 206010053884 trisomy 18 Diseases 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B20/00—Methods specially adapted for identifying library members
- C40B20/04—Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
- C40B60/10—Apparatus specially adapted for use in combinatorial chemistry or with libraries for identifying library members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32903001P | 2001-10-12 | 2001-10-12 | |
| US60/329,030 | 2001-10-12 | ||
| PCT/US2002/033044 WO2003091426A1 (en) | 2001-10-12 | 2002-10-15 | Compilations of nucleic acids and arrays and methods of using them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2463725A1 true CA2463725A1 (en) | 2003-11-06 |
Family
ID=29270419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002463725A Abandoned CA2463725A1 (en) | 2001-10-12 | 2002-10-15 | Compilations of nucleic acids and arrays and methods of using them |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7335470B2 (enExample) |
| EP (1) | EP1451318A4 (enExample) |
| JP (1) | JP2005519634A (enExample) |
| AU (1) | AU2002367886B8 (enExample) |
| CA (1) | CA2463725A1 (enExample) |
| WO (1) | WO2003091426A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0878552A1 (en) * | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
| EP1078098A1 (en) | 1998-05-04 | 2001-02-28 | Dako A/S | Method and probes for the detection of chromosome aberrations |
| US6979728B2 (en) * | 1998-05-04 | 2005-12-27 | Baylor College Of Medicine | Articles of manufacture and methods for array based analysis of biological molecules |
| US20050032060A1 (en) * | 2001-08-31 | 2005-02-10 | Shishir Shah | Arrays comprising pre-labeled biological molecules and methods for making and using these arrays |
| US7439346B2 (en) | 2001-10-12 | 2008-10-21 | Perkinelmer Las Inc. | Nucleic acids arrays and methods of use therefor |
| US7335470B2 (en) | 2001-10-12 | 2008-02-26 | Perkinelmer, Las, Inc. | Compilations of nucleic acids and arrays and methods of using them |
| US20090075841A1 (en) * | 2002-10-15 | 2009-03-19 | Johnson Robert C | Nucleic acids arrays and methods of use therefor |
| EP1576192B1 (en) * | 2002-12-23 | 2014-10-29 | Agilent Technologies, Inc. | Comparative genomic hybridization assays using immobilized oligonucleotide features and compositions for practicing the same |
| WO2005049866A2 (en) * | 2003-11-14 | 2005-06-02 | Duke University | Methods of detecting charcot-marie tooth disease type 2a |
| US20070031883A1 (en) * | 2004-03-04 | 2007-02-08 | Kincaid Robert H | Analyzing CGH data to identify aberrations |
| US8321138B2 (en) * | 2005-07-29 | 2012-11-27 | Agilent Technologies, Inc. | Method of characterizing quality of hybridized CGH arrays |
| WO2005113834A2 (en) | 2004-05-20 | 2005-12-01 | Quest Diagnostics Investments Incorporated | Single label comparative hybridization |
| EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US20060130157A1 (en) | 2004-10-22 | 2006-06-15 | Kevin Wells | Ungulates with genetically modified immune systems |
| AU2005333165B2 (en) | 2004-11-12 | 2012-07-19 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US20070072175A1 (en) * | 2005-05-13 | 2007-03-29 | Biogen Idec Ma Inc. | Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof |
| US8076074B2 (en) * | 2005-11-29 | 2011-12-13 | Quest Diagnostics Investments Incorporated | Balanced translocation in comparative hybridization |
| WO2007095007A2 (en) * | 2006-02-14 | 2007-08-23 | Albert Einstein College Of Medicine Of Yeshiva University | Systematic genomic library and uses thereof |
| WO2008030065A1 (en) * | 2006-09-08 | 2008-03-13 | Macrogen Inc. | Microarray chip and method for detection of chromosomal abnormality |
| CA2663962A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| AU2007299828C1 (en) | 2006-09-19 | 2014-07-17 | Interpace Diagnostics, Llc | MicroRNAs differentially expressed in pancreatic diseases and uses thereof |
| US20080102453A1 (en) * | 2006-10-31 | 2008-05-01 | Jayati Ghosh | Methods and systems and analysis of CGH data |
| US7507539B2 (en) * | 2007-07-30 | 2009-03-24 | Quest Diagnostics Investments Incorporated | Substractive single label comparative hybridization |
| EP2198050A1 (en) | 2007-09-14 | 2010-06-23 | Asuragen, INC. | Micrornas differentially expressed in cervical cancer and uses thereof |
| GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
| EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| US20100159506A1 (en) * | 2008-07-25 | 2010-06-24 | Cellscape Corporation | Methods and systems for genetic analysis of fetal nucleated red blood cells |
| JP5331404B2 (ja) * | 2008-08-01 | 2013-10-30 | 国立大学法人 東京医科歯科大学 | 先天性異常症の染色体欠失の検出方法 |
| EP2320883A4 (en) * | 2008-08-14 | 2012-12-26 | Nestec Sa | COMPOSITIONS AND METHODS FOR INFLUENCING SATURATION, FAT SWITCHING AND GREASE EVALUATION |
| DK2348827T3 (en) | 2008-10-27 | 2015-07-20 | Revivicor Inc | IMMUNICIPLY COMPROMATED PETS |
| JPWO2011049237A1 (ja) * | 2009-10-23 | 2013-03-14 | 公益財団法人東京都医学総合研究所 | 減感作療法における治療効果を予測するバイオマーカー |
| WO2011067234A2 (en) * | 2009-12-02 | 2011-06-09 | Roche Diagnostics Gmbh | Multiplexed microarray and method of fabricating thereof |
| EP3214174B1 (en) | 2010-03-04 | 2019-10-16 | InteRNA Technologies B.V. | A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt |
| US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
| EP2591106A1 (en) | 2010-07-06 | 2013-05-15 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| US9803236B2 (en) * | 2010-08-06 | 2017-10-31 | Tsinghua University | Microarray-based assay integrated with particles for analyzing molecular interactions |
| AU2011329772B2 (en) | 2010-11-17 | 2017-05-04 | Interpace Diagnostics, Llc | miRNAs as biomarkers for distinguishing benign from malignant thyroid neoplasms |
| EP2561102A1 (en) | 2010-12-02 | 2013-02-27 | Katholieke Universiteit Leuven K.U. Leuven R&D | Irak-related interventions and diagnosis |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| MX2013009863A (es) | 2011-02-28 | 2013-12-06 | Univ Iowa Res Found | Cambios de la hormona anti-mulleriana en el embarazo y prediccion de sexo y de resultados adversos en el embarazo. |
| US8753873B2 (en) | 2011-04-15 | 2014-06-17 | Roche Nimblegen, Inc. | Multiplexed microarray assembly and method for fabricating a multiplexed microarray |
| US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
| US20130157884A1 (en) | 2011-10-26 | 2013-06-20 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
| EP2771487A1 (en) | 2011-10-27 | 2014-09-03 | Asuragen, INC. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
| EP2870263A1 (en) | 2012-07-03 | 2015-05-13 | InteRNA Technologies B.V. | Diagnostic portfolio and its uses |
| WO2014055117A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
| CA2907377A1 (en) | 2013-03-15 | 2014-09-18 | Baylor Research Institute | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
| US9944992B2 (en) | 2013-03-15 | 2018-04-17 | The University Of Chicago | Methods and compositions related to T-cell activity |
| WO2014151551A1 (en) | 2013-03-15 | 2014-09-25 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
| ES2421207B1 (es) * | 2013-05-31 | 2014-04-15 | Universidad De León | Procedimiento y kit de diagnóstico de lisencefalia con hipoplasia cerebelar en ganado ovino |
| EP3110973B1 (en) | 2014-02-27 | 2019-02-06 | Katholieke Universiteit Leuven | Oxidative stress and cardiovascular disease events |
| US10704097B2 (en) | 2014-02-27 | 2020-07-07 | Katholieke Universiteit Leuven | Oxidative stress and cardiovascular disease events |
| DK3234112T3 (da) | 2014-12-19 | 2020-03-02 | Univ Brussel Vrije | In vitro-modning af et pattedyre-cumulus-oocytkompleks |
| WO2019086603A1 (en) | 2017-11-03 | 2019-05-09 | Interna Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| US12276654B2 (en) | 2017-11-22 | 2025-04-15 | The University Of Chicago | Chemical probe-dependent evaluation of protein activity and uses thereof |
| CN114174532A (zh) | 2019-04-05 | 2022-03-11 | 德克萨斯大学系统董事会 | 细胞条形码编码的方法和应用 |
| JP7566775B2 (ja) | 2019-04-12 | 2024-10-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 筋肉量及び酸化的代謝を増加させるための組成物及び方法 |
| WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
| WO2025248505A1 (en) | 2024-05-31 | 2025-12-04 | Wayne State University | Methods for treating endometrial and ovarian hyperproliferative disorders |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55116259A (en) | 1979-03-01 | 1980-09-06 | Fuji Photo Film Co Ltd | Microimmunoassay method |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| DE3170135D1 (en) | 1980-09-02 | 1985-05-30 | Fuji Photo Film Co Ltd | Method for immunochemical measurement of trace components |
| US4355153A (en) | 1980-11-19 | 1982-10-19 | Societa' Italiana Resine S.I.R. S.P.A. | Process for the polymerization of formaldehyde |
| CA1253129A (en) | 1984-02-09 | 1989-04-25 | Thomas R. Jones | Porous inorganic materials |
| US4957858A (en) | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| US4818681A (en) | 1985-02-22 | 1989-04-04 | Molecular Diagnostics, Inc. | Fast and specific immobilization of nucleic acids to solid supports |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5641630A (en) | 1985-06-13 | 1997-06-24 | Amgen Inc. | Method and kit for performing nucleic acid hybridization assays |
| US4806631A (en) | 1985-09-30 | 1989-02-21 | Miles Inc. | Immobilization of nucleic acids on solvolyzed nylon supports |
| US4652613A (en) | 1985-12-16 | 1987-03-24 | Celanese Corporation | Novel elastomer/oxymethylene polymer blends containing polymeric compatibilizing agents |
| US5721098A (en) | 1986-01-16 | 1998-02-24 | The Regents Of The University Of California | Comparative genomic hybridization |
| US5190864A (en) | 1986-04-15 | 1993-03-02 | Northeastern University | Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material |
| US4937188A (en) | 1986-04-15 | 1990-06-26 | Northeastern University | Enzyme activity amplification method for increasing assay sensitivity |
| US6048982A (en) | 1986-04-18 | 2000-04-11 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
| US5268486A (en) | 1986-04-18 | 1993-12-07 | Carnegie-Mellon Unversity | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
| US5151507A (en) | 1986-07-02 | 1992-09-29 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
| US5047519A (en) | 1986-07-02 | 1991-09-10 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
| US5135717A (en) | 1986-12-24 | 1992-08-04 | British Technology Group Usa Inc. | Tetrabenztriazaporphyrin reagents and kits containing the same |
| US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
| DE3880273T2 (de) | 1987-11-27 | 1993-07-29 | Ecc Int Ltd | Poroese anorganische materialien. |
| GB8803413D0 (en) | 1988-02-15 | 1988-03-16 | Ecc Int Ltd | Biological support |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5024933A (en) | 1988-05-10 | 1991-06-18 | Enzo Biochem, Inc. | Method and kit for sample adherence to test substrate |
| US5602244A (en) | 1988-05-26 | 1997-02-11 | Competitive Technologies, Inc. | Polynucleotide phosphorodithioate compounds |
| CA2045129A1 (en) | 1989-02-01 | 1990-08-02 | Alfred I. Geller | Herpes simplex virus type i expression vector |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6309822B1 (en) | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US6416952B1 (en) | 1989-06-07 | 2002-07-09 | Affymetrix, Inc. | Photolithographic and other means for manufacturing arrays |
| US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| DE3929150A1 (de) | 1989-09-02 | 1991-03-07 | Akzo Gmbh | Cellulosische membranen |
| US5188934A (en) | 1989-11-14 | 1993-02-23 | Applied Biosystems, Inc. | 4,7-dichlorofluorescein dyes as molecular probes |
| US5215882A (en) | 1989-11-30 | 1993-06-01 | Ortho Diagnostic Systems, Inc. | Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays |
| FR2659349B1 (fr) | 1990-03-12 | 1993-12-24 | Rhone Merieux | Virus herpes recombinants notamment pour la realisation de vaccins, leur procede de preparation, les plasmides realises au cours de ce procede et les vaccins obtenus. |
| US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
| US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
| US5227487A (en) | 1990-04-16 | 1993-07-13 | Molecular Probes, Inc. | Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes |
| DK0455905T3 (da) | 1990-05-11 | 1998-12-07 | Microprobe Corp | Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider |
| US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
| US5817462A (en) | 1995-02-21 | 1998-10-06 | Applied Spectral Imaging | Method for simultaneous detection of multiple fluorophores for in situ hybridization and multicolor chromosome painting and banding |
| US5936731A (en) | 1991-02-22 | 1999-08-10 | Applied Spectral Imaging Ltd. | Method for simultaneous detection of multiple fluorophores for in situ hybridization and chromosome painting |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| US5300687A (en) | 1991-07-18 | 1994-04-05 | Ortho Pharmaceutical Corporation | Trifluoromethylbenzylphosphonates useful in treating osteoporosis |
| US5288625A (en) | 1991-09-13 | 1994-02-22 | Biologic Research Center Of The Hungarian Academy Of Sciences | Mammalian artificial chromosomes |
| US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
| US5846708A (en) | 1991-11-19 | 1998-12-08 | Massachusetts Institiute Of Technology | Optical and electrical methods and apparatus for molecule detection |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5652099A (en) | 1992-02-12 | 1997-07-29 | Conrad; Michael J. | Probes comprising fluorescent nucleosides and uses thereof |
| JPH05236997A (ja) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | ポリヌクレオチド捕捉用チップ |
| DE69330750T2 (de) | 1992-03-04 | 2002-07-04 | The Regents Of The University Of California, Oakland | Vergleichende genomhybridisierung |
| US5965362A (en) | 1992-03-04 | 1999-10-12 | The Regents Of The University Of California | Comparative genomic hybridization (CGH) |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| EP0767361B1 (en) | 1993-07-22 | 2000-02-23 | Applied Spectral Imaging Ltd. | Method and apparatus for spectral imaging |
| WO1995003400A1 (en) | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
| US6001982A (en) | 1993-07-29 | 1999-12-14 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| US5637687A (en) | 1993-08-31 | 1997-06-10 | Wiggins; James C. | Methods and compositions for isolating nucleic acids |
| US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| ES2325393T3 (es) | 1993-10-28 | 2009-09-03 | Houston Advanced Research Center | Aparato poroso de flujo a traves microfabricado para la deteccion diferenciada de reacciones de union. |
| US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
| US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
| US5610287A (en) | 1993-12-06 | 1997-03-11 | Molecular Tool, Inc. | Method for immobilizing nucleic acid molecules |
| DE4344726C2 (de) | 1993-12-27 | 1997-09-25 | Deutsches Krebsforsch | Verfahren zum Nachweis von nicht balanciertem genetischen Material einer Spezies oder zum Nachweis der Genexpression in Zellen einer Spezies |
| US6028190A (en) | 1994-02-01 | 2000-02-22 | The Regents Of The University Of California | Probes labeled with energy transfer coupled dyes |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| EP0695941B1 (en) | 1994-06-08 | 2002-07-31 | Affymetrix, Inc. | Method and apparatus for packaging a chip |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5554744A (en) | 1994-09-23 | 1996-09-10 | Hybridon, Inc. | Method for loading solid supports for nucleic acid synthesis |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5830645A (en) * | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US5601982A (en) | 1995-02-07 | 1997-02-11 | Sargent; Jeannine P. | Method and apparatus for determining the sequence of polynucleotides |
| US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
| US5635351A (en) | 1995-03-14 | 1997-06-03 | The Regents Of The University Of California | Genetic gain and loss in gliomas |
| US5863504A (en) | 1995-03-16 | 1999-01-26 | Bio-Rad Laboratories, Inc. | Fluorescence imaging instrument utilizing fish |
| US5962674A (en) | 1995-06-01 | 1999-10-05 | Hybridon, Inc. | Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages |
| EP0831854A4 (en) | 1995-06-06 | 2001-01-24 | Isis Pharmaceuticals Inc | OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY |
| US5614386A (en) | 1995-06-23 | 1997-03-25 | Baylor College Of Medicine | Alternative dye-labeled primers for automated DNA sequencing |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| FR2736342B1 (fr) | 1995-07-07 | 1999-01-29 | Univ Claude Bernard Lyon | Procede pour la fabrication d'aerogels de silice monolithiques et aerogels de silice ainsi obtenus |
| US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| US5630932A (en) | 1995-09-06 | 1997-05-20 | Molecular Imaging Corporation | Tip etching system and method for etching platinum-containing wire |
| US5734041A (en) | 1995-10-20 | 1998-03-31 | Mcgill University | Preparation of chiral phosphorothioate oligomers |
| US5721118A (en) | 1995-10-31 | 1998-02-24 | The Regents Of The University Of California, San Diego | Mammalian artificial chromosomes and methods of using same |
| US6143495A (en) | 1995-11-21 | 2000-11-07 | Yale University | Unimolecular segment amplification and sequencing |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| US5714386A (en) | 1996-01-11 | 1998-02-03 | Board Of Trustees Of The Leland Stanford Junior University | Cy7-allophycocyanin conjugates for use in multiplex fluorescence detection assays |
| US20010018514A1 (en) | 1998-07-31 | 2001-08-30 | Mcgall Glenn H. | Nucleic acid labeling compounds |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
| US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| AU3568897A (en) | 1996-06-07 | 1998-01-05 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
| US5880473A (en) | 1997-07-28 | 1999-03-09 | Applied Imaging, Inc. | Multifluor-fluorescence in-situ hybridization (M-FISH) imaging techniques using multiple multiband filters with image registration |
| US6027709A (en) | 1997-01-10 | 2000-02-22 | Li-Cor Inc. | Fluorescent cyanine dyes |
| US5790727A (en) | 1997-02-05 | 1998-08-04 | Brookhaven Science Associates Llc | Laser illumination of multiple capillaries that form a waveguide |
| JPH10227740A (ja) | 1997-02-18 | 1998-08-25 | Hitachi Ltd | 多色蛍光検出電気泳動分析装置 |
| US6048457A (en) | 1997-02-26 | 2000-04-11 | Millipore Corporation | Cast membrane structures for sample preparation |
| US5846726A (en) | 1997-05-13 | 1998-12-08 | Becton, Dickinson And Company | Detection of nucleic acids by fluorescence quenching |
| US6063338A (en) | 1997-06-02 | 2000-05-16 | Aurora Biosciences Corporation | Low background multi-well plates and platforms for spectroscopic measurements |
| US5919626A (en) * | 1997-06-06 | 1999-07-06 | Orchid Bio Computer, Inc. | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
| US5939261A (en) | 1997-06-24 | 1999-08-17 | Sarnoff Corporation | Method for capturing a nucleic acid |
| US6096817A (en) | 1997-06-26 | 2000-08-01 | E. I. Du Pont De Nemours And Company | Mixtures of polyimides and elastomers |
| US5914039A (en) | 1997-07-01 | 1999-06-22 | Zenon Environmental Inc. | Filtration membrane with calcined α-alumina particles therein |
| US6826296B2 (en) | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
| US5943129A (en) | 1997-08-07 | 1999-08-24 | Cambridge Research & Instrumentation Inc. | Fluorescence imaging system |
| US6294331B1 (en) | 1997-08-08 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for assessing genetic and phenotypic markers by simultaneous multicolor visualization of chromogenic dyes using brightfield microscopy and spectral imaging |
| CA2300940A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
| US6223127B1 (en) | 1997-08-15 | 2001-04-24 | Affymetrix, Inc. | Polymorphism detection utilizing clustering analysis |
| US6294327B1 (en) | 1997-09-08 | 2001-09-25 | Affymetrix, Inc. | Apparatus and method for detecting samples labeled with material having strong light scattering properties, using reflection mode light and diffuse scattering |
| AU733589B2 (en) | 1997-09-11 | 2001-05-17 | Bioventures, Inc. | Method of making high density arrays |
| US6465178B2 (en) | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
| US6060324A (en) | 1997-11-12 | 2000-05-09 | Phytochem Technologies, Inc. | Fluorometric assay composition for measurement of antioxidant activity |
| US6049380A (en) | 1997-11-12 | 2000-04-11 | Regents Of The University Of California | Single molecule identification using selected fluorescence characteristics |
| US5922617A (en) | 1997-11-12 | 1999-07-13 | Functional Genetics, Inc. | Rapid screening assay methods and devices |
| US5874259A (en) | 1997-11-21 | 1999-02-23 | Wisconsin Alumni Research Foundation | Conditionally amplifiable BAC vector |
| US5936087A (en) | 1997-11-25 | 1999-08-10 | The Perkin-Elmer Corporation | Dibenzorhodamine dyes |
| US6277621B1 (en) | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
| US6077673A (en) | 1998-03-31 | 2000-06-20 | Clontech Laboratories, Inc. | Mouse arrays and kits comprising the same |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| US6183957B1 (en) | 1998-04-16 | 2001-02-06 | Institut Pasteur | Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria |
| US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
| SE514568C2 (sv) | 1998-05-18 | 2001-03-12 | Allgon Ab | Antennanordning omfattande matningsmedel och en handburen radiokommunikationsanordning för en sådan antennanordning |
| CA2339163C (en) | 1998-08-10 | 2010-01-12 | Genomic Solutions, Inc. | Thermal and fluidic cycling device for nucleic acid hybridization |
| US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
| WO2000026412A1 (en) | 1998-11-02 | 2000-05-11 | Kenneth Loren Beattie | Nucleic acid analysis using sequence-targeted tandem hybridization |
| US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
| US6235504B1 (en) | 1999-01-11 | 2001-05-22 | The Rockefeller University | Methods for identifying genomic equivalent markers and their use in quantitating cells and polynucleotide sequences therein |
| AU2965500A (en) | 1999-01-15 | 2000-08-01 | Gene Logic, Inc. | Immobilized nucleic acid hybridization reagent and method |
| US6251601B1 (en) * | 1999-02-02 | 2001-06-26 | Vysis, Inc. | Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays |
| WO2000047600A1 (en) | 1999-02-10 | 2000-08-17 | University Of Maryland | Photo-induced nucleic acid hybridization |
| US6277581B1 (en) | 1999-03-01 | 2001-08-21 | Lankenau Medical Research Center | ODC allelic analysis method for assessing carcinogenic susceptibility |
| US6221653B1 (en) | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
| WO2001001144A2 (en) | 1999-06-30 | 2001-01-04 | Iris Bio Technologies | Hybridization of target dna with immobilized nucleic acid analogs |
| US6294338B1 (en) | 1999-07-23 | 2001-09-25 | Gen-Probe Incorporated | Polynucleotide amplification method |
| US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
| US6252664B1 (en) | 1999-10-15 | 2001-06-26 | Biocrystal Ltd. | Fluorescence filter cube for fluorescence detection and imaging |
| US6383749B2 (en) | 1999-12-02 | 2002-05-07 | Clontech Laboratories, Inc. | Methods of labeling nucleic acids for use in array based hybridization assays |
| US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
| DK1132739T3 (da) * | 2000-05-16 | 2002-01-28 | Biochip Technologies Gmbh | Linkersystem til aktivering af overflader til biokonjugation og fremgangsmåder til anvendelse deraf |
| US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| JP4502167B2 (ja) * | 2001-07-06 | 2010-07-14 | 大日本印刷株式会社 | マイクロアレイチップ |
| US7335470B2 (en) | 2001-10-12 | 2008-02-26 | Perkinelmer, Las, Inc. | Compilations of nucleic acids and arrays and methods of using them |
-
2002
- 2002-10-15 US US10/273,399 patent/US7335470B2/en not_active Expired - Fee Related
- 2002-10-15 AU AU2002367886A patent/AU2002367886B8/en not_active Ceased
- 2002-10-15 EP EP02807317A patent/EP1451318A4/en not_active Withdrawn
- 2002-10-15 WO PCT/US2002/033044 patent/WO2003091426A1/en not_active Ceased
- 2002-10-15 CA CA002463725A patent/CA2463725A1/en not_active Abandoned
- 2002-10-15 JP JP2003587960A patent/JP2005519634A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002367886B8 (en) | 2008-08-14 |
| AU2002367886A1 (en) | 2003-11-10 |
| WO2003091426A1 (en) | 2003-11-06 |
| EP1451318A4 (en) | 2007-06-27 |
| JP2005519634A (ja) | 2005-07-07 |
| US20040009493A1 (en) | 2004-01-15 |
| US7335470B2 (en) | 2008-02-26 |
| AU2002367886B2 (en) | 2008-02-28 |
| EP1451318A1 (en) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7335470B2 (en) | Compilations of nucleic acids and arrays and methods of using them | |
| US7439346B2 (en) | Nucleic acids arrays and methods of use therefor | |
| US7351529B2 (en) | Methods for detecting genetic mosaicisms using arrays | |
| US20230183788A1 (en) | Oligonucleotide Paints | |
| US20050014184A1 (en) | Arrays, computer program products and methods for in silico array-based comparative binding arrays | |
| AU2002330141A1 (en) | Methods for detecting genetic mosaicisms using arrays | |
| JP2007515947A (ja) | 羊水中の無細胞胎児ｄｎａを使用する出生前診断 | |
| US20020094518A1 (en) | Determining signal transduction pathways | |
| US20090075841A1 (en) | Nucleic acids arrays and methods of use therefor | |
| US8021888B2 (en) | Rapid comparative genomic hybridization using acoustic surface waves | |
| US20030124542A1 (en) | Methods for mapping the chromosomal loci of genes expressed by a cell | |
| US20060003342A1 (en) | Fetal RNA in amniotic fluid to determine gene expression in the developing fetus | |
| US20250283156A1 (en) | Parallel multiple displacement amplification method | |
| CA2534441A1 (en) | Arrays, methods and kits for preparation and use of syntenic genomic arrays for diagnostics and toxicology | |
| Gallardo et al. | Application to Assisted Reproductive of Whole-Genome Treatment Technologies | |
| Hurley et al. | Molecular approaches to the study of gene expression during human preimplantation development | |
| CA2513028A1 (en) | Fetal rna in amniotic fluid to determine gene expression in the developing fetus | |
| Gallardo et al. | Application of Whole-Genome Technologies to Assisted Reproductive Treatment | |
| Class et al. | Inventors: Chao-Ting Wu (Brookline, MA, US) Chao-Ting Wu (Brookline, MA, US) George M. Church (Brookline, MA, US) Benjamin Richard Williams (Seattle, WA, US) Assignees: President and Fellows of Havard College | |
| TÖNNIES | Molecular Molecular Cytogenetics Diagnostics in | |
| EXT et al. | Chromosomal localization Name Involved gene (s)/hybridization target | |
| AU2005203357A1 (en) | Fetal RNA in amniotic fluid to determine gene expression in the developing fetus | |
| CA2350976A1 (en) | Cell libraries indexed to nucleic acid microarrays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20121022 |